193 related articles for article (PubMed ID: 14973508)
1. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
García-Sanz R; González-Porras JR; Hernández JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; López R; Grande-García C; Alegre A; Vargas-Pabón M; Gutiérrez ON; Rodríguez JA; San Miguel JF
Leukemia; 2004 Apr; 18(4):856-63. PubMed ID: 14973508
[TBL] [Abstract][Full Text] [Related]
2. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
3. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
[TBL] [Abstract][Full Text] [Related]
5. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
García-Sanz R; González-Fraile MI; Sierra M; López C; González M; San Miguel JF
Hematol J; 2002; 3(1):43-8. PubMed ID: 11960395
[TBL] [Abstract][Full Text] [Related]
6. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
10. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
[TBL] [Abstract][Full Text] [Related]
11. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
12. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Gao W; An N; Chen SL
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M
Haematologica; 2001 Apr; 86(4):399-403. PubMed ID: 11325646
[TBL] [Abstract][Full Text] [Related]
16. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
19. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.
Dmoszynska A; Walter-Croneck A; Hus I; Grzasko N; Manko J; Jedrzejczak WW; Charlinski G; Usnarska-Zubkiewicz L; Skotnicki A; Wolska-Smolen T; Piszcz J; Kloczko J
Leuk Res; 2010 Oct; 34(10):1330-5. PubMed ID: 20627385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
